Magnesium for Vascular Dysregulation in Glaucoma and Aging Circulation

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/magnesium-for-vascular-dysregulation-in-glaucoma-and-aging-circulation

Test your visual field online: https://visualfieldtest.com

Excerpt:

Magnesium and Vascular Dysregulation in GlaucomaGlaucoma is a progressive optic nerve disease that leads to vision loss. While high intraocular pressure (IOP) is the best-known risk factor, many patients – especially those with normal-tension glaucoma (NTG) – develop glaucoma despite normal IOP (). In NTG, systemic vascular issues are believed to contribute: unstable blood flow, vasospasm (sudden vessel constriction), and excessive nighttime blood pressure dips can reduce blood supply to the optic nerve () (). Treatments that stabilize blood flow are therefore of interest in NTG. Magnesium, an essential mineral and natural calcium-channel blocker, has emerged as a candidate because it promotes vasodilation and nerve protection ().Magnesium’s Vascular ActionsMagnesium influences blood vessels and endothelial function in several ways:Calcium antagonism. Magnesium acts as a physiologic calcium channel blocker. It competes with calcium in muscle and blood vessels, causing smooth muscle relaxation and vasodilation. () In laboratory studies, raising Mg²⁺ levels inhibits endothelin-1–induced vessel constriction (for example, in porcine ciliary arteries) (). Because endothelin-1 is a powerful vasoconstrictor implicated in glaucoma, magnesium’s blockade of this pathway can improve perfusion. () Endothelial function. Healthy blood vessels produce relaxing factors like nitric oxide (NO). Magnesium enhances endothelial cell health and NO availability, leading to better blood flow. () Studies in coronary artery disease show that oral magnesium improves endothelium-dependent vasodilation (). By improving the balance of endothelin-1 vs. nitric oxide, magnesium can reduce abnormal vasoconstriction and oxidative stress in tiny ocular vessels. Vasospasm relief. Clinically, many NTG patients have Raynaud-like vasospasm (cold-triggered digital or nailfold spasms). In one pilot study of 10 glaucoma patients with cold-induced fingertip vasospasm, giving 121.5 mg magnesium twice daily for one month significantly improved peripheral capillary flow and digital temperature, and visual fields tended to improve (). This suggests magnesium can relieve systemic vasospasm, potentially stabilizing ocular perfusion (). Magnesium also has neuroprotective effects. By blocking NMDA receptors and inhibiting excitotoxic glutamate release, Mg²⁺ guards against retinal ganglion cell damage (). It stabilizes neuronal metabolism (supporting ATP production and antioxidants) (). In summary, magnesium helps normalize blood vessel tone and protect nerve cells – both relevant in glaucoma-related vascular dysregulation () ().Blood Pressure Dipping and Ocular PerfusionHealthy individuals have a 10–20% drop in blood pressure during sleep. Some glaucoma patients, especially NTG, experience excessive overnight dips or total hypotension, harming optic nerve perfusion. A landmark longitudinal study found that NTG patients whose mean arterial pressure stayed ≥10 mmHg below daytime levels for longer during sleep were much more likely to experience progressive visual field loss (). In other words, nocturnal hypotension (deep nighttime dips) predicted glaucomatous progression ().Magnesium status appears to influence this blood pressure rhythm. Low magnesium labs are linked to a non-dipping pattern – where nighttime BP fails to decline normally (). In hypertensive patients, hypomagnesemia blunted the normal nocturnal dip, likely via increased sympathetic activity and altered renin-angiotens